KR20240099226A9 - 항원 결합 폴리펩티드, 항원 결합 폴리펩티드 복합체 및 hiv에서 이의 사용 방법 - Google Patents

항원 결합 폴리펩티드, 항원 결합 폴리펩티드 복합체 및 hiv에서 이의 사용 방법

Info

Publication number
KR20240099226A9
KR20240099226A9 KR1020247014156A KR20247014156A KR20240099226A9 KR 20240099226 A9 KR20240099226 A9 KR 20240099226A9 KR 1020247014156 A KR1020247014156 A KR 1020247014156A KR 20247014156 A KR20247014156 A KR 20247014156A KR 20240099226 A9 KR20240099226 A9 KR 20240099226A9
Authority
KR
South Korea
Prior art keywords
antigen
binding
hiv
methods
polypeptide complexes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247014156A
Other languages
English (en)
Korean (ko)
Other versions
KR20240099226A (ko
Inventor
로니 롱 웨이
링 수
지-용 양
게리 제이. 나벨
Original Assignee
모덱스 테라퓨틱스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 모덱스 테라퓨틱스, 인크. filed Critical 모덱스 테라퓨틱스, 인크.
Publication of KR20240099226A publication Critical patent/KR20240099226A/ko
Publication of KR20240099226A9 publication Critical patent/KR20240099226A9/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C07K16/1145—Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • AIDS & HIV (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020247014156A 2021-09-29 2022-09-28 항원 결합 폴리펩티드, 항원 결합 폴리펩티드 복합체 및 hiv에서 이의 사용 방법 Pending KR20240099226A9 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163249722P 2021-09-29 2021-09-29
US63/249,722 2021-09-29
PCT/US2022/077203 WO2023056315A1 (en) 2021-09-29 2022-09-28 Antigen binding polypeptides, antigen binding polypeptide complexes and methods of use thereof in hiv

Publications (2)

Publication Number Publication Date
KR20240099226A KR20240099226A (ko) 2024-06-28
KR20240099226A9 true KR20240099226A9 (ko) 2025-12-10

Family

ID=85783606

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247014156A Pending KR20240099226A9 (ko) 2021-09-29 2022-09-28 항원 결합 폴리펩티드, 항원 결합 폴리펩티드 복합체 및 hiv에서 이의 사용 방법

Country Status (13)

Country Link
US (1) US20250197481A1 (https=)
EP (1) EP4408892A4 (https=)
JP (1) JP2024537827A (https=)
KR (1) KR20240099226A9 (https=)
CN (1) CN118660907A (https=)
AR (1) AR127176A1 (https=)
AU (1) AU2022357501A1 (https=)
CA (1) CA3232365A1 (https=)
CL (1) CL2024000890A1 (https=)
IL (1) IL311762A (https=)
MX (1) MX2024003804A (https=)
TW (1) TW202325744A (https=)
WO (1) WO2023056315A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116574748B (zh) * 2023-07-10 2023-09-12 昆明医科大学 一种用于靶向KRAS高频突变肿瘤的嵌合型nTCR-T构建方法
WO2025162460A1 (zh) * 2024-02-04 2025-08-07 南通壹宸生物医药科技有限公司 一种轭合化合物及其制备和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI743461B (zh) * 2011-03-28 2021-10-21 法商賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
MX353382B (es) * 2012-03-01 2018-01-10 Amgen Res Munich Gmbh Moleculas de union polipeptido de larga duracion.
US9458244B2 (en) * 2012-12-28 2016-10-04 Abbvie Inc. Single chain multivalent binding protein compositions and methods
RS62437B1 (sr) * 2015-10-25 2021-11-30 Sanofi Sa Trispecifični i/ili trivalentni vezujući proteini za prevenciju ili lečenje hiv infekcije
CA3020633A1 (en) * 2016-04-13 2017-10-19 Sanofi Trispecific and/or trivalent binding proteins
WO2018075564A1 (en) * 2016-10-17 2018-04-26 University Of Maryland, College Park Multispecific antibodies targeting human immunodeficiency virus and methods of using the same
US12365722B2 (en) * 2018-10-19 2025-07-22 University Of Maryland, College Park Multispecific antibodies targeting multiple epitopes on the HIV-1 envelope
AU2019372673A1 (en) * 2018-11-01 2021-05-27 Gracell Biotechnologies (Shanghai) Co., Ltd. Compositions and methods for T cell engineering
TW202104274A (zh) * 2019-04-09 2021-02-01 法商賽諾菲公司 用於治療ｈｉｖ感染之三特異性及／或三價結合蛋白

Also Published As

Publication number Publication date
JP2024537827A (ja) 2024-10-16
CN118660907A (zh) 2024-09-17
IL311762A (en) 2024-05-01
AU2022357501A1 (en) 2024-04-18
EP4408892A4 (en) 2025-11-19
CA3232365A1 (en) 2023-04-06
WO2023056315A1 (en) 2023-04-06
KR20240099226A (ko) 2024-06-28
AR127176A1 (es) 2023-12-27
MX2024003804A (es) 2024-06-11
EP4408892A1 (en) 2024-08-07
US20250197481A1 (en) 2025-06-19
CL2024000890A1 (es) 2024-10-11
TW202325744A (zh) 2023-07-01

Similar Documents

Publication Publication Date Title
KR20240099223A9 (ko) 항원 결합 폴리펩티드, 항원 결합 폴리펩티드 복합체 및 이의 사용 방법
SI4011908T1 (sl) Ultra dolgo delujoči inzulin-fc fuzijski proteini in postopki uporabe
LT3997103T (lt) Junginiai, apimantys fibroblastų aktyvinimo baltymo ligandą, ir jų panaudojimas
KR20240099226A9 (ko) 항원 결합 폴리펩티드, 항원 결합 폴리펩티드 복합체 및 hiv에서 이의 사용 방법
EP3858856A4 (en) ANTI-B7-H3 MONOCLONAL ANTIBODY AND ITS USE IN CELL THERAPY
IL280317A (en) Anti-avb8 antibodies and compositions and uses thereof
EA201891589A1 (ru) Условно активные гетеродимерные полипептиды и способы их применения
MX2021003475A (es) Metodos de purificacion de proteinas.
DK3772927T3 (da) Genetisk modificerede mus eller rotter til generering af terapeutiske antistoffer mod peptid¿MHC-komplekser, fremgangsmåde til fremstilling og anvendelser deraf
JOP20190097A1 (ar) الجلوبولينات المناعية واستخداماتها
IL280809B (en) Novel compositions, their use, and methods for their formation
DK3917626T3 (da) Psma-bindende dualmodusradiotracer og terapeutika
EP4365203A4 (en) ANTIGEN-BINDING POLYPEPTIDE TARGETING B7H3 AND ITS APPLICATION
EP3887389A4 (en) Polypeptides and methods for improving skin conditions
DK4073098T5 (da) Ultralangtidsvirkende insulin-Fc-fusionsproteiner og fremgangsmåder til anvendelse
IL287374A (en) Anti-proliferative agents for treating pah
EP3999544A4 (en) POLYPEPTIDE COMPLEX FOR CONJUGATION AND ITS USE
EP4433497A4 (en) D-DOMAIN POLYPEPTIDES AND ASSOCIATED USES
IL304607A (en) Compositions comprising pedf-derived short peptides (pdsp) and uses thereof
EP4453020A4 (en) LILRB POLYPEPTIDES AND THEIR USES
EP4359425A4 (en) REGENERATIVE POLYPEPTIDES AND THEIR USES
IL290509A (en) Antibodies that bind to lrp5 proteins and methods of use
EA201792269A1 (ru) Полипептиды, нацеленные на слияние вич
IL304157A (en) Cd8 polypeptides, compositions, and methods of using thereof
IL309780A (en) Anti-protac antibodies and complexes

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P19 Errors in documents containing ipogçös decisions corrected

Free format text: ST27 STATUS EVENT CODE: A-3-3-P10-P19-OTH-PG1701 (AS PROVIDED BY THE NATIONAL OFFICE)

PG1701 Publication of correction

St.27 status event code: A-3-3-P10-P19-oth-PG1701

Patent document republication publication date: 20251210

Republication note text: Request for Correction Notice (Document Request)

Gazette number: 1020240099226

Gazette reference publication date: 20240628

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000